Welcoming Atripla

McManus, Michael
August 2006
Advocate;8/29/2006, Issue 969, p47
The article reports on the approval of the antiretroviral HIV/AIDS drug Atripla from Bristol-Mayers Squibb by the U.S. Food and Drug Administration. When the first antiretroviral HIV/AIDS drugs were approved by the Food and Drug Administration 10 years ago, many patients were taking more than 20 pills just to stay alive. Now people with HIV and their doctors across the country are celebrating the approval of Atripla, the first single daily pill for the treatment of the disease. Atripla is the result of a unique partnership between Bristol-Myers Squibb and Gilead Sciences, two leading pharmaceutical companies.


Related Articles

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p27 

    The article offers news briefs related to infectious diseases. GlaxoSmithKline PLC was criticized by some AIDS advocates for the voluntary licensing agreement it granted to produce generic AIDS drugs for use in South Africa. Bristol-Myers Squibb Co. and Gilead Sciences Inc. have formed a joint...

  • HARD TO SWALLOW. Roehr, Bob // Just Out;1/7/2005, Vol. 22 Issue 5, p15 

    Reports that pharmaceutical firms Bristol-Myers Squibb Co. and Gilead Sciences Inc. have collaborated to produce a single anti-HIV pill that contains multiple drugs. Drugs produced by Bristol and Gilead; Need of clinical trials to demonstrate that packing the drugs all into the same pill results...

  • HIV-25 YEARS LATER. Belden, Heidi // Drug Topics;11/20/2006, Vol. 150 Issue 22, p36 

    The article focuses on various developments related to AIDS prevention in the United States as of November 20, 2006. One important development was the Food and Drug Administration's approval of Tibotec's darunavir Prezista for marketing in June 2006. Another development was the introduction of...

  • Combination drug for HIV.  // Cortlandt Forum;Oct2006, Vol. 19 Issue 10, p18 

    The article offers information about Atripla, an antiretroviral agent, from Bristol-Myers Squibb Co. and Gilead. The drug is a combination of three anti-HIV drugs which includes Sustiva, Emtriva and Viread. Furthermore, Atripla was approved by the Food and Drug Administration based on clinical...

  • Over the Next Decade, the Dominance of Bristol-Myers Squibb/Gilead's Atripla in the HIV Drug Market Will Be Challenged by Gilead's Quad and Gilead/Janssen's Complera.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p464 

    The article reports on the expected sales growth of the HIV drugs Quad from Gilead Sciences Inc. and Complera from Gilead and Janssen Therapeutics. It mentions that Quad and Complera are expected to challenge Bristol-Myers Squibb Co. and Gilead's Atripla in the HIV drug market. It notes that...

  • Barr Says FDA Approves Generic Version of Anti-HIV Drug.  // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, preceding p1 

    This article reports that Barr Pharmaceuticals Inc. on Friday said the Food and Drug Administration approved the company's generic version of Videx EC, an antiretroviral drug developed by Bristol-Myers Squibb Co.

  • Merck's HCV Regimen 'C-Worthy' in Early Test; Competitive Waters Ahead. Boggs, Jennifer // BioWorld Today;11/5/2013, Vol. 24 Issue 213, p1 

    The article reports on the shift of attention to Merck & Co. Inc. and other companies developing all-oral treatment regimens for hepatitis C virus (HCV) as a similar regimen developed by Gilead Sciences Inc. is poised to receive approval from the U.S. Food and Drug Administration (FDA) in 2013....

  • Saxagliptin + Metformin Extended-release Tablets (Kombiglyze XR). Elliott, William T.; Chan, James // Internal Medicine Alert;1/15/2011, Vol. 33 Issue 1, p5 

    The article reports on the approval of Saxagliptin + Metformin Extended-release tablets, a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin combination from Bristol-Myers Squibb by the U.S. Food and Drug Administration (FDA).

  • Pharma: Other News To Note.  // BioWorld Today;11/5/2012, Vol. 23 Issue 215, p8 

    This article reports on the decision of the National Institute of Health and Clinical Excellence in Great Britain to recommend Bristol-Myers Squibb Co.'s Yervoy, which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics